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The concept of ‘‘G2 checkpoint abrogation’’ in combination with
various chemotherapeutic drugs is currently successfully
explored in clinical trials. The anti-cancer drug UCN-01 allows
the entry into mitosis in the presence of DNA damage selectively
in p53 defective tumor cells.
We show here that this leads to a mitotic arrest and to the
activation of a branch of the mitotic spindle checkpoint that mon-
itors the lack of tension across kinetochores involving the func-
tion of Mad2, Bub1, BubR1, Mps1, Aurora B and survivin.
Subsequently mitotic cell death, also known as ‘‘mitotic catastro-
phe’’, is induced, which potentiates the efficacy of standard che-
motherapy. Interestingly, mitotic cell death is associated with the
activation of the mitochondria associated apoptosis pathway,
thus, we refer to it as mitotic apoptosis. Importantly, while the
mitotic arrest in response to UCN-01 is dependent on the spindle
checkpoint, only the checkpoint component Mad2 is required for
the execution of mitotic apoptosis suggesting that Mad2 might
have an additional function as a pro-apoptotic protein. Signifi-
cantly, the mitotic apoptosis is counteracted by a survivin depen-
dent survival pathway. Thus, the mitotic apoptosis is a result of a
balance between pro- and anti-apoptotic pathways. Most impor-
tantly, pharmacologiocal interference with Aurora B, CDK1 or
PI3-kinase modulating the levels of survivin leads to a significant
increase of apoptosis in response to UCN-01. Thus, our results
suggest a highly improved strategy for anti-cancer treatment
using UCN-01 and abrogators of a mitotic survivin dependent sur-
vivial pathway without neglecting the selectivity of UCN-01 for
p53 defective cancer cells.
doi:10.1016/j.ejcsup.2006.04.036
S36. VIRAL ONCOGENES CAUSING HUMAN CANCERS
Harald zur Hausen. Deutsches Krebsforschungszentrum, Im
Neuenheimer Feld 280, 69120 Heidelberg, Germany.
Research of the past 25 years resulted in the identification of a
number of infectious agents engaged in the etiology of in part
very common human cancers. Among the latter are cervical
cancer and hepatocellular carcinomas. Members of several dif-
ferent virus families possess oncogenic potential: these are pap-
illomaviruses (e.g. HPV 16 and 18), herpes group viruses
(Epstein-Barr virus and human herpesvirus type 8), Hepatitis B
and Hepatitis C virus, Human T-lymphotropic retrovirus type 1
(HTLV-1). Most of these agents contain oncogenes and act as
‘‘direct carcinogens’’. The functions of these oncogenes have
been partially characterized and will be discussed. Humans
and their cells infected by these viruses are commonly able to
cope with these infections by intra- and intercellular surveil-
lance mechanisms or by immunological interference. Cancer
development requires a modification of genes within the signal-
ling pathways regulating the intra- and intercellular defense.
Part of the modifications of cellular genes is also mediated by
viral oncogenes.
Besides direct carcinogenic functions via oncogenes, other
agents contribute to human cancer by rather indirect modes.
This seems to be the case in hepatitis B and C infections where
the induction of oxygen radicals apparently plays a significant
role in cancer induction. Human immunodeficiency viruses
(HIV) promote cancer induction by other viruses due to the
induction of immunosuppression. Possible other mechanisms
of indirect carcinogenesis by infectious agents will also be
discussed.
doi:10.1016/j.ejcsup.2006.04.037
S37. ONCOPROTECTIVE PARVOVIRUSES IN CANCER THERAPY
Jean Rommelaere. Deutsches Krebsforschungszentrum, Abt. F010
and INSERM U701, Heidelberg, Germany.
As a result of their oncotropism, oncolytic effect and low inflam-
matory activity, some autonomous parvoviruses open up new
prospects to the fight against cancer and were tested for their
safety in pilot phase I clinical trials. Preclinical studies in animal
models showed that the parvoviruses H-1PV and MVM are
endowed with a genuine oncosuppressive capacity, for which var-
ious tumours can be targets. However, the antineoplastic poten-
tial of these agents is insufficient, in many instances, for
tumours to irreversibly regress. Efforts are thus made to improve
the oncosuppressive activity of parvoviruses, using different
strategies. On the one hand, discrete modifications are intro-
duced into the parvoviral genome so as to keep its infectiousness
while stimulating its antineoplastic properties. Parvovirus
mutants were engineered so that their capacity for tumour cell
lysis or immune cell activation is enhanced. On the other hand,
parvoviruses are used as vectors to generate recombinants that
are able to deliver therapeutic transgenes in target cells. MVM
and H-1PV-based vectors transducing and expressing anti-angio-
genic and/or immunomodulating factors were more particularly
produced. Appropriate combinations of these recombinant vec-
tors were found to efficiently suppress highly vascularised
tumours, e.g. gliomas, in animal models. On the basis of these
data, the promise of the application of parvoviruses to cancer
viro- and gene therapy will be discussed.
doi:10.1016/j.ejcsup.2006.04.038
S38. PROPHYLACTIC VACCINES AGAINST CERVICAL CANCER
Lutz Gissmann. DKFZ, Heidelberg, Germany.
Since several years it has been accepted that persistent infection
with certain (so called-high risk: HR) types of Human papillom-
aviruses (HPV) represents a strong risk factor for cervical cancer.
The most frequent HR HPV types 16 and 18 account for about
70% of this tumour, which is the second most frequent malig-
nancy in women worldwide. Several studies in animal papillo-
mavirus models revealed that protection against infection is
conferred by neutralizing antibodies directed against conforma-
tional epitopes of the major structural protein L1. Such antibod-
ies can most efficiently be induced by immunization with virus-
like particles (VLP) that assemble spontaneously following
expression of L1 in recombinant vectors. Large-scale production
of HPV 16 and 18 VLPs proved to be successful facilitating, a few
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years ago, first clinical trials on safety and immunogenicity. In
the meantime more than 25,000 women have been included into
several efficacy trials which demonstrated protection against
persistent infection with HPV 16 and 18 and against the develop-
ment of precursor lesions to cervical cancer. Although the ulti-
mate proof of success, i.e. reduction of cancer incidence still
requires the immunization of large populations and many years
of follow-up, the existing data are so persuasive that the first
marketing of the vaccine is expected to be announced in mid
2006. Yet several questions such as the duration of protection,
the need development of for post-exposure vaccination strate-
gies and availability of such vaccine in low-budget countries
are open and will be discussed.
doi:10.1016/j.ejcsup.2006.04.039
S39. IDENTIFICATION OF POTENTIAL TARGET ANTIGENS FOR
IMMUNOTHERAPY APPROACHES
Dirk Ja¨ger. Medizinische Onkologie, Nationales Centrum fu¨r
Tumorerkrankungen, Universita¨tsklinik Heidelberg, Germany.
Immunotherapy approaches in cancer rely on the identification of
suitable antigens that can be used as targets for therapeutic
approaches. The ideal target antigen is highly and homogenously
expressed in cancer, but not or low level expressed in normal tis-
sues. Using different cloning techniques, several potential target
antigens have been identified, some of these antigens are already
being evaluated in clinical trials. We followed a cloning strategy
called SEREX that identifies tumor antigens based on a spontane-
ous humoral immune response in patients. Using this technique
we identified 2 new tumor associated antigens that belong to the
group of differentiation antigens: NY-BR-1 as a new breast differ-
entiation antigen and RAB38/NY-MEL-1 as a new melanocyte dif-
ferentiation antigen.
NY-BR-1 is not expressed in normal tissues except in nor-
mal mammary gland and testis, but it is highly expressed in
70% of breast cancers. Antigen positive cancers maintain the
expression in metastatic lesions. Spontaneous antibody
responses occur in about 10% of breast cancer patients. We
identified 2 HLA-A2 restricted NY-BR-1 derived epitopes that
were recognized by CD8+ T cells from patients with NY-BR-1
expressing cancers. Both epitopes are naturally processed and
presented.
RAB38/NY-MEL-1 is expressed in melanocytes and at low level
in adrenal gland, all other normal tissues are RAB38/NY-MEL-1
mRNA negative. Spontaneous humoral immune responses are
frequent in melanoma patients but not in normal individuals,
in patients with vitiligo or with cancers other than melanoma.
We recently identified a HLA-A2 restricted RAB38/NY-MEL-1
derived epitope that is naturally processed and presented and
recognized by CD8 T cells.
Both new antigens, NY-BR-1 and RAB38/NY-MEL-1 are being
evaluated as targets for T cell based immunotherapy strategies
in Phase-I trials.
doi:10.1016/j.ejcsup.2006.04.040
S40. T CELL BASED IMMUNOTHERAPY – CHANGES AND
CHALLENGES
Volker Schirrmacher. Division of Cellular Immunology, German
Cancer Research Center, Heidelberg, Germany.
Advances in cellular and molecular immunology have led to the
development of strategies for effective augmentation of anti-
tumor immune-responses in cancer patients. This presentation
focuses on the manipulation of T cell immunity either by
active-specific immunization with tumor vaccines1–4 or by adop-
tive immunotherapy with immune T cells.5,6 Such therapies offer
exquisite specificity of tumor recognition based on the ability of
the T cell to distinguish single amino acid differences in any pro-
tein from any compartment of the tumor cell.
Recent analyses of bone marrow samples from patients with
a variety of different cancers revealed the existence of cancer
reactive memory T cells in a high proportion and at high fre-
quencies.5–9 A fine specificity analysis revealed individuality (i)
of response patterns to multiple tumor associated antigens
(TAAs), (ii) of the size and (iii) of the specificity of the memory
repertoire in the bone marrow of cancer patients. These findings
challenge immunotherapy approaches targeting single TAAs.
Future strategies will be discussed for the exploitation of the
TAA memory repertoire of cancer patients. In ‘‘proof of princi-
ple’’ studies it was demonstrated to have great therapeutic
potential.5,6
REFERENCES
1. Schirrmacher, V.. Expert Opinion on Biol Ther, 5(8), 1051–1068.
2. Steiner, H. H. et al. J Clin Oncol, 22(21), 4272–4281.
3. Karcher, J. et al. Cancer Res, 64(21), 8057–8061.
4. Schirrmacher, V.. Cancer Immunol Immunother, 54/6, 587–598.
5. Feuerer, M. et al. Nat Med, 7(4), 452–458.
6. Beckhove, P. et al. J Clin Invest, 114, 67–76.
7. Feuerer, M. et al. Nat Med, 9, 1151–1157.
8. Choi, C. et al. Blood, 105(5), 2132–2134.
9. Schmitz-Winnenthal, F. et al. Cancer Res, 65(21), 10079–10087.
doi:10.1016/j.ejcsup.2006.04.041
S41. TARGETING THE APOPTOTIC PATHWAY TO INDUCE
RADIORESISTANCE IN NORMAL TISSUE AND STEM CELLS
Frederik Wenz. Department of Radiation Oncology, Mannheim
Medical Center, University of Heidelberg, Germany.
Novel strategies in clinical radiotherapy have the goal to
increase the therapeutic index i.e. effective tumor cell kill while
sparing the normal tissue. This can be achieved by either phys-
ical selectivity when the tumor is well circumscribed or by bio-
logical selectivity when normal tissue is present in the
treatment volume. Biological selectivity can be achieved by tar-
geting tissue properties which are only present either in tumor
or normal tissue cells.
Radiation induced apoptosis is a rare event as compared to
mitogenic death in epithelial tumor cells. In contrast, radiation
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